vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $281.3M, roughly 1.2× Guardant Health, Inc.). WYNDHAM HOTELS & RESORTS, INC. runs the higher net margin — -18.0% vs -45.7%, a 27.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -4.6%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
GH vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $334.0M |
| Net Profit | $-128.5M | $-60.0M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | -18.0% |
| Revenue YoY | 39.4% | -76.3% |
| Net Profit YoY | -15.8% | -170.6% |
| EPS (diluted) | $-1.01 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $281.3M | $334.0M | ||
| Q3 25 | $265.2M | $382.0M | ||
| Q2 25 | $232.1M | $397.0M | ||
| Q1 25 | $203.5M | $316.0M | ||
| Q4 24 | $201.8M | $336.0M | ||
| Q3 24 | $191.5M | $396.0M | ||
| Q2 24 | $177.2M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $-128.5M | $-60.0M | ||
| Q3 25 | $-92.7M | $105.0M | ||
| Q2 25 | $-99.9M | $87.0M | ||
| Q1 25 | $-95.2M | $61.0M | ||
| Q4 24 | $-111.0M | $85.0M | ||
| Q3 24 | $-107.8M | $102.0M | ||
| Q2 24 | $-102.6M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | -11.4% | ||
| Q3 25 | -37.3% | 46.6% | ||
| Q2 25 | -45.9% | 37.8% | ||
| Q1 25 | -54.6% | 35.4% | ||
| Q4 24 | -62.4% | 38.4% | ||
| Q3 24 | -61.3% | 43.2% | ||
| Q2 24 | -56.8% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | -45.7% | -18.0% | ||
| Q3 25 | -35.0% | 27.5% | ||
| Q2 25 | -43.0% | 21.9% | ||
| Q1 25 | -46.8% | 19.3% | ||
| Q4 24 | -55.0% | 25.3% | ||
| Q3 24 | -56.3% | 25.8% | ||
| Q2 24 | -57.9% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $-1.01 | $-0.77 | ||
| Q3 25 | $-0.74 | $1.36 | ||
| Q2 25 | $-0.80 | $1.13 | ||
| Q1 25 | $-0.77 | $0.78 | ||
| Q4 24 | $-0.90 | $1.06 | ||
| Q3 24 | $-0.88 | $1.29 | ||
| Q2 24 | $-0.84 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $64.0M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $468.0M |
| Total Assets | $2.0B | $4.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $378.2M | $64.0M | ||
| Q3 25 | $580.0M | $70.0M | ||
| Q2 25 | $629.1M | $50.0M | ||
| Q1 25 | $698.6M | $48.0M | ||
| Q4 24 | $525.5M | $103.0M | ||
| Q3 24 | $585.0M | $72.0M | ||
| Q2 24 | $933.7M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $2.5B | ||
| Q3 25 | $1.1B | $2.6B | ||
| Q2 25 | $1.1B | $2.5B | ||
| Q1 25 | $1.1B | $2.5B | ||
| Q4 24 | $1.1B | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $-99.3M | $468.0M | ||
| Q3 25 | $-354.5M | $583.0M | ||
| Q2 25 | $-305.5M | $570.0M | ||
| Q1 25 | $-250.8M | $579.0M | ||
| Q4 24 | $-139.6M | $650.0M | ||
| Q3 24 | $-60.1M | $583.0M | ||
| Q2 24 | $-1.6M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $2.0B | $4.2B | ||
| Q3 25 | $1.3B | $4.3B | ||
| Q2 25 | $1.3B | $4.3B | ||
| Q1 25 | $1.3B | $4.2B | ||
| Q4 24 | $1.5B | $4.2B | ||
| Q3 24 | $1.5B | $4.2B | ||
| Q2 24 | $1.6B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.37× | ||
| Q3 25 | — | 4.43× | ||
| Q2 25 | — | 4.44× | ||
| Q1 25 | — | 4.29× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $367.0M |
| Free Cash FlowOCF − Capex | $-54.2M | $168.0M |
| FCF MarginFCF / Revenue | -19.3% | 50.3% |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $-26.4M | $152.0M | ||
| Q3 25 | $-35.4M | $86.0M | ||
| Q2 25 | $-60.3M | $70.0M | ||
| Q1 25 | $-62.7M | $59.0M | ||
| Q4 24 | $-64.5M | $134.0M | ||
| Q3 24 | $-51.1M | $79.0M | ||
| Q2 24 | $-94.0M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $-54.2M | $136.0M | ||
| Q3 25 | $-45.8M | $75.0M | ||
| Q2 25 | $-65.9M | $58.0M | ||
| Q1 25 | $-67.1M | $52.0M | ||
| Q4 24 | $-83.4M | $109.0M | ||
| Q3 24 | $-55.3M | $71.0M | ||
| Q2 24 | $-99.1M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | -19.3% | 40.7% | ||
| Q3 25 | -17.3% | 19.6% | ||
| Q2 25 | -28.4% | 14.6% | ||
| Q1 25 | -33.0% | 16.5% | ||
| Q4 24 | -41.3% | 32.4% | ||
| Q3 24 | -28.9% | 17.9% | ||
| Q2 24 | -55.9% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 4.8% | ||
| Q3 25 | 3.9% | 2.9% | ||
| Q2 25 | 2.4% | 3.0% | ||
| Q1 25 | 2.2% | 2.2% | ||
| Q4 24 | 9.4% | 7.4% | ||
| Q3 24 | 2.2% | 2.0% | ||
| Q2 24 | 2.9% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.82× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.97× | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
